Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

Summary

The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related macular degeneration (AMD) . This study was to provide long-term safety data in the treatment of Chinese patients with wet AMD.

Timeline

Start

2013-02-22

Primary completion

2015-11-23

Completion

2015-11-23

Outcome

Met primary endpoint

registry analysis (unspecified test); Ranibizumab 0.5 mg Monthly vs Ranibizumab 0.5 mg PRN; Mean Difference (Final Values) -1.6 (95% CI -2.95 to -0.2); ANOVA NCT01775124 ↗

Drugs

Indications